Month: May 2023

This article or press release has no online content. Please download the associated documents for more information.Attachment2022-Half-year-financial-report

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201 Best responder duration of response was 16.5 months with response ongoing as of the data cutoff date of May 11, 2023LOS ANGELES, May 21, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma...

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respiratory symptoms COPD is the third leading cause of death worldwide, with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate-to-severe disease and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells/µL) TARRYTOWN, N.Y. and PARIS, May 21, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals,...

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineDupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respiratory symptoms COPD is the third leading cause of death worldwide, with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate-to-severe disease and evidence of...

As announced after the Annual General Meeting of Iceland Seafood on March 16th the company’s board of directors was given an authorization to increase the company’s share capital by up to ISK 150.000.000 nominal value. The board of directors has now decided to utilize this authorization in full, to strengthen the company’s financial position. The share increase is done in accordance with paragraph 3 of Article 4 of the company’s Articles of Association. In total 150.000.000 new shares will be issued, Investors have subscribed for all the shares at a price of 6.00 per share, which is equal to the highest bid on Nasdaq Iceland at end of Friday May 19th. The new shares will be paid for in cash, they will be issued electronically and registered at Nasdaq CDN and the registration at the Company Registry of the Iceland Revenue and Customs. Total...

Eleven-university strong network to grow the next-generation workforce and advance semiconductor-based research in both countries HIROSHIMA, Japan, May 20, 2023 (GLOBE NEWSWIRE) — Micron Technology, Inc., the largest foreign investor in Japan over the last five years, today announced the launch of the U.S.-Japan University Partnership for Workforce Advancement and Research & Development in Semiconductors (UPWARDS) for the Future. Aimed at cultivating a more robust and highly-skilled semiconductor workforce for the two countries, the partnership will drive emerging research while increasing the pipeline of students studying a semiconductor curriculum. U.S. Secretary of State Antony J. Blinken and Japanese Minister of Education, Culture, Sports, Science and Technology Keiko Nagaoka presided over the signing of a memorandum of...

Figure 2 REDWOOD-HCM Cohort 4: Angina SymptomsFigure 1 REDWOOD-HCM Cohort 4: Kansas City Cardiomyopathy Questionnaire (KCCQ)Figure 4 REDWOOD-HCM Cohort 4: Cardiac BiomarkersFigure 3 REDWOOD-HCM Cohort 4: New York Heart Association (NYHA) Functional ClassTreatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2, open-label clinical trial of aficamten in patients with non-obstructive...

Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, CA. “Our Gene Circuits are poised to potentially disrupt high-priority, unmet need diseases with smarter cell and gene therapies that can confer better activity, precision, and control,” said Timothy Lu, M.D., Ph.D., Chief Executive Officer...

AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN), (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today announced that it intends to offer its securities in a firm commitment underwritten public offering (the “Offering”). The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital, operating expenses and capital expenditures. The offering is expected to close on May 24, 2023, subject to customary conditions. Aegis Capital Corp. is acting as the sole book-running manager for the Offering. The Company signed a securities purchase and exchange agreement (the “Agreement”) on May 19, 2023 to (1) issue an investor approximately $5 million original principal amount of nine (9) month convertible senior notes (the “New...

JACKSONVILLE, Fla., May 19, 2023 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) has been recognized by intermodal providers as the top-performing railroad in North America. The “Intermodal Service Scorecard” ranking was compiled by the Journal of Commerce, and assessed performance through the first four months of 2023. To create the Scorecard, more than 100 shippers and intermodal marketing companies were invited to perform a satisfaction assessment. Respondents cited their satisfaction with domestic intermodal service as a key driver of CSX’s number one ranking. Customers highlighted improvements in the railroad’s fluidity, train speed and customer service. “CSX is proud to be recognized by our customers for the quality of our service delivery,” said President and CEO Joe Hinrichs. “CSX’s service performance has returned to — or in...